- Home
- NVRI vs GPCR Comparison
NVRI vs GPCR Comparison
Compare NVRI & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRI
- GPCR
- Stock Information
- Founded
- NVRI 1853
- GPCR 2016
- Country
- NVRI United States
- GPCR United States
- Employees
- NVRI N/A
- GPCR N/A
- Industry
- NVRI Diversified Commercial Services
- GPCR
- Sector
- NVRI Miscellaneous
- GPCR
- Exchange
- NVRI Nasdaq
- GPCR Nasdaq
- Market Cap
- NVRI 911.3M
- GPCR 1.1B
- IPO Year
- NVRI N/A
- GPCR 2023
- Fundamental
- Price
- NVRI $11.76
- GPCR $22.08
- Analyst Decision
- NVRI Hold
- GPCR Strong Buy
- Analyst Count
- NVRI 1
- GPCR 9
- Target Price
- NVRI $10.00
- GPCR $75.63
- AVG Volume (30 Days)
- NVRI 1.3M
- GPCR 1.2M
- Earning Date
- NVRI 10-30-2025
- GPCR 08-06-2025
- Dividend Yield
- NVRI N/A
- GPCR N/A
- EPS Growth
- NVRI N/A
- GPCR N/A
- EPS
- NVRI N/A
- GPCR N/A
- Revenue
- NVRI $2,242,873,000.00
- GPCR N/A
- Revenue This Year
- NVRI N/A
- GPCR N/A
- Revenue Next Year
- NVRI $3.72
- GPCR N/A
- P/E Ratio
- NVRI N/A
- GPCR N/A
- Revenue Growth
- NVRI N/A
- GPCR N/A
- 52 Week Low
- NVRI $4.72
- GPCR $13.22
- 52 Week High
- NVRI $11.97
- GPCR $45.37
- Technical
- Relative Strength Index (RSI)
- NVRI 71.63
- GPCR 68.89
- Support Level
- NVRI $10.81
- GPCR $18.49
- Resistance Level
- NVRI $11.97
- GPCR $21.23
- Average True Range (ATR)
- NVRI 0.46
- GPCR 1.25
- MACD
- NVRI 0.08
- GPCR 0.28
- Stochastic Oscillator
- NVRI 91.12
- GPCR 95.74
About NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.